---
title: "11:34 ETShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293494670.md"
description: "Ademi LLP is investigating BioLife Solutions (NASDAQ: BLFS) regarding its proposed acquisition by Repligen. The firm questions whether the board fulfilled fiduciary duties, citing potential breaches due to change-of-control benefits for insiders and restrictive provisions limiting competing bids. Shareholders are offered $11.25 cash plus 0.1442 Repligen shares per share, totaling $31.00. Ademi invites shareholders to join the investigation to determine if a fair price was obtained."
datetime: "2026-07-22T15:35:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293494670.md)
  - [en](https://longbridge.com/en/news/293494670.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293494670.md)
---

# 11:34 ETShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders

, /PRNewswire/ -- Ademi LLP is investigating BioLife (NASDAQ: BLFS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Repligen.

Click here to learn how to join our investigation and obtain additional information or contact us at \[email protected\] or toll-free: 866-264-3995. There is no cost or obligation to you.

BioLife shareholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, equating to a total value of $31.00 per share, for a total enterprise value of approximately $1.5 billion. The consideration is structured as 64% Repligen common stock and 36% cash.

BioLife insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for BioLife by imposing a significant penalty if BioLife accepts a competing bid. We are investigating the conduct of the BioLife board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP  
Guri Ademi  
Toll Free: (866) 264-3995  
Fax: (414) 482-8001

SOURCE Ademi LLP

### Related Stocks

- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)

## Related News & Research

- [BioLife Solutions Q2 revenue rises 21% year over year](https://longbridge.com/en/news/295138582.md)
- [Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals](https://longbridge.com/en/news/294739855.md)
- [Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a share](https://longbridge.com/en/news/293454273.md)
- [Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns](https://longbridge.com/en/news/294466535.md)
- [Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?](https://longbridge.com/en/news/293625486.md)